|Day Low/High||15.17 / 15.57|
|52 Wk Low/High||8.16 / 15.74|
They're the kind of names, along with a big dollop of cash in my portfolio, I plan to wait out the 'trade wars'.
The trio consists of BioDelivery Sciences International, Beazer Homes USA and Redhill Biopharma.
Mortgage rates have been declining of late, which should help produce a better story for the housing market in the second part of 2019.
I do think consolidation across this very fragmented industry will pick up in the quarters ahead.
An owner of radio stations, a homebuilder and a wellness company still offer value even after the broader market's run to record highs.
Builder confidence has ticked up of late heading into the crucial spring selling season.
Investors are already more focused on what lies ahead when Q1 results start in early April.
Small cap stocks should see much faster earnings growth than larger concerns.
I still like some of the names in this sector to rally further off oversold levels.
This homebuilder has roared past resistance.
The homebuilder shot up 30% on Tuesday after crushing earnings expectations and likely won't be the only bet to pay off in the sector.
The never-ending strength now seen in the dollar is causing the most pain in U.S. markets.
William Lyons Homes and Beazer Homes appear to have bad news already priced into their depressed shares.
.We haven't seen these type of earnings gains since 2010
They are LGI Homes, Beazer Homes, Prestige Consumer Healthcare, Gulfport Energy and Cabot Oil.
These data points tell me investors are too pessimistic on this part of the market.
We have confirmation that things are pretty good for home builders and related 'nesting' stocks.
Beazer Homes, Great Lakes Dredge & Dock and Entercom Communications seem like bargains right now.
I continue to deploy some of the 'dry powder' into the market after its recent hiccup.
The planet will likely never ever need to consume less energy tomorrow than it did yesterday.
Consumer confidence is up, but savings is down, which will curb first-time buyers' housing demand.
This biopharma company's Relistor drug should send revenues sharply higher this year.
This biopharma company's Relistor drug should send revenues sharply higher next year.
Traders, investors see demand as a function of confidence rather than capacity.
This is one housing stock that looks attractive from the long side